High drug costs are systemic, rooted in the for-profit model's legal obligation to prioritize shareholder returns over patient affordability. This is compounded by a complex distribution chain where multiple middlemen—wholesalers, insurers, and pharmacies—each add a profit layer, inflating the final price.

The high cost of insulin isn't from manufacturing but from the complex distribution chain of wholesalers, pharmacies, and insurers. Project Insulin's core strategy is to bypass this system entirely with a direct-to-patient mail-order pharmacy model, effectively eliminating the middlemen who inflate the final price.

Contrary to the narrative of government inefficiency, Medicare's administrative overhead is only 2%. In contrast, private commercial insurers spend 16% of every dollar on administration, advertising, and claim disputes, revealing a major source of bloat in the US healthcare system.

Rising premiums and deductibles are pushing people away from traditional insurance. This isn't an abandonment of healthcare, but a market response to a product that no longer provides adequate value, forcing a shift towards cash-pay and alternative models.

A significant hidden cost in the US healthcare system is the administrative expense of price negotiation. For a well-run hospital, the process of billing, negotiating, and receiving reimbursement from insurance companies can consume 2% to 7% of a patient's total bill, adding a substantial layer of inefficiency.

The US healthcare market suffers because massive, consolidated hospital systems and payers create negotiating "loggerheads." With no viable alternatives, they reach inefficient agreements where costs are inflated for everyone. A more fragmented market with smaller players would foster more genuine and effective price competition.

The rise of cash-pay proactive health creates a two-tier system. One group can afford to defect from insurance and build their own health stack, while another cycles through the traditional system, relying on charity care, exacerbating inequity.

The idea of a single, equitable healthcare system is often a myth. Regardless of the official structure, a cash-pay system for faster or better care will almost always emerge for those who can afford it, a reality policymakers must acknowledge.

Beyond low-cost generic drugs, Cuban's company negotiates directly with hospitals for better prices. The truly disruptive move is publishing this transparent contract online (at costpluswellness.com), empowering any self-insured business to bypass insurance middlemen and access the same pre-negotiated rates.